

BASIS FOR THE AMENDMENT

The specification has been amended to correct a minor typographical error.

Claims 3, 4, 13 and 14 are canceled.

Claim 1 has been amended as supported by Claim 14 as originally filed.

No new matter is believed to have been added by entry of this amendment. Entry and favorable reconsideration are respectfully requested.

Upon entry of this amendment Claims 1, 2 and 5-12, 15-21 will now be active in this application.

REMARKS

Applicants respectfully request reconsideration of the application, as amended, in view of the following remarks.

The present invention as set forth in **amended Claim 1** relates to a modified polyolefin resin produced by

subjecting a polyolefin resin (A) to a graft modification by vinyl monomer(s) (B) comprising **4-t-butylcyclohexyl (meth)acrylate**;

wherein the vinyl monomer(s) (B) comprises no unsaturated carboxylic acid or its anhydride.

The rejection of the claims over Ilenda (US4,957,974) and over a combination of Ilenda (US4,957,974) and Usui (US6,800,688) is traversed.

Ilenda (US4,957,974) and Usui (US6,800,688) fail to disclose or suggest the use of **4-t-butylcyclohexyl (meth)acrylate**.

Ilenda only discloses the use of cyclohexyl methacrylate (col. 7, lines 57-58). There is no disclosure or suggestion to use **4-t-butylcyclohexyl (meth)acrylate**.

Further, Applicants previously distinguished from Usui by claiming that monomer (B) comprises no unsaturated carboxylic acid or its anhydride. As a result the rejection over Usui was withdrawn. Usui also fails to disclose or suggest the use of **4-t-butylcyclohexyl (meth)acrylate**.

In addition, the Examples in the present invention show that 4-t-butylcyclohexyl (meth)acrylate is superior compared to cyclohexyl (meth)acrylate, for example in terms of adhesion peel strength.


Compare Ex. 2 and Ex. 6 (now comparative) at page 36 of the specification. The use of 4-t-butylcyclohexyl (meth)acrylate results in higher adhesion peel strength. Similarly for a comparison of Ex. 5 and Ex. 7 (now comparative); and for a comparison of Ex. 10 with Ex. 12 (now comparative). This is not disclosed or suggested by Ilenda (US4,957,974) and Usui (US6,800,688), alone or in combination.

Thus, the rejection of the claims over Ilenda (US4,957,974) and over a combination of Ilenda (US4,957,974) and Usui (US6,800,688) should be withdrawn.

This application presents allowable subject matter, and the Examiner is kindly requested to pass it to issue. Should the Examiner have any questions regarding the claims or otherwise wish to discuss this case, he is kindly invited to contact Applicants' below-signed representative, who would be happy to provide any assistance deemed necessary in speeding this application to allowance.

Respectfully submitted,

OBLON, SPIVAK, McCLELLAND,
MAIER & NEUSTADT, P.C.
Norman F. Oblon


Kirsten A. Grueneberg, Ph.D.
Registration No.: 47,297

Customer Number
22850

Tel: (703) 413-3000
Fax: (703) 413 -2220
NFO:KAG:
(OSMMN 08/07)